NeonMind Biosciences Past Earnings Performance
Past criteria checks 0/6
NeonMind Biosciences has been growing earnings at an average annual rate of 36.8%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually.
Key information
36.8%
Earnings growth rate
56.4%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 28 Feb 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How NeonMind Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
28 Feb 23 | 0 | -1 | 1 | 0 |
30 Nov 22 | 0 | -2 | 1 | 0 |
31 Aug 22 | 0 | -2 | 2 | 1 |
31 May 22 | 0 | -4 | 3 | 1 |
28 Feb 22 | 0 | -5 | 5 | 1 |
30 Nov 21 | 0 | -7 | 6 | 1 |
31 Aug 21 | 0 | -7 | 5 | 1 |
31 May 21 | 0 | -6 | 5 | 0 |
28 Feb 21 | 0 | -4 | 3 | 0 |
30 Nov 20 | 0 | -2 | 1 | 0 |
Quality Earnings: NEON is currently unprofitable.
Growing Profit Margin: NEON is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NEON is unprofitable, but has reduced losses over the past 5 years at a rate of 36.8% per year.
Accelerating Growth: Unable to compare NEON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: NEON's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.